Q-linea AB (QLINEA) Price & Analysis

Compare

3 Followers

QLINEA Stock Chart & Stats

kr29.00

>-kr0.01(-3.85%)

At close: Mar 06 4:00 PM EST

kr29.00

>-kr0.01(-3.85%)

Day’s Range― - ―

52-Week Rangekr20.79 - kr74.06

Previous CloseN/A

Volume6.05M

Average Volume (3M)13.43K

Market Cap

kr408.72M

Enterprise Value-kr104.21M

Total Cash (Recent Filing)kr258.11M

Total Debt (Recent Filing)kr7.71M

Price to Earnings (P/E)―

Beta3.13

Next Earnings

Apr 30, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-3.73

Shares Outstanding18,949,081

10 Day Avg. Volume10,725

30 Day Avg. Volume13,430

Financial Highlights & Ratios

PEG Ratio>-0.01

Price to Book (P/B)0.49

Price to Sales (P/S)14.97

P/FCF Ratio-0.98

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-5.51

Revenue Forecast (FY)kr107.00M

Bulls Say, Bears Say

Bulls Say

Recurring Consumables RevenueQ-linea’s commercial model couples instrument placements with repeat consumable sales. As installed base and test volumes scale, consumable demand can generate predictable, recurring revenue and improve revenue visibility and long-term margin leverage if unit costs and pricing stabilize.

Clinical Focus On Sepsis DiagnosticsThe company targets hospital microbiology and sepsis workflows, a structurally important clinical area where faster AST materially impacts patient outcomes. Persistent clinical need and hospital prioritization support sustained demand for rapid diagnostics and recurring test volumes over time.

Low Reported LeverageReported low debt and minimal debt-to-equity in 2025 reduce near-term refinancing and interest-rate risk. This financial flexibility supports continued R&D and commercialization investments without immediate debt servicing pressure, important while commercial scale-up proceeds.

Bears Say

Negative Gross ProfitNegative gross profit indicates product-level costs currently exceed revenues, undermining unit economics. Even with recurring sales, sustained negative gross margins make profitable scaling unlikely without material cost reductions, higher pricing, or improved assay yields and throughput.

Persistent Heavy Cash BurnConsistently large negative operating and free cash flows (roughly -SEK160m to -268m) show ongoing cash consumption. Continued burn forces reliance on external financing, increases dilution risk, and constrains the company’s ability to sustain commercial expansion or absorb operational setbacks.

Unstable Capital StructureA prior period of negative equity reflects significant capital erosion and financial stress. Such volatility in the capital structure raises the likelihood of future equity raises under duress, which can dilute existing holders and complicate long-term strategic planning.

Q-linea AB News

Q-linea Nomination Committee Proposes Stable Board and New Expertise Ahead of 2026 AGM

The latest update is out from Q-linea AB ( ($SE:QLINEA) ). Q-linea AB’s nomination committee has proposed a...

6d ago

Q-linea Boosts Capital and Global Footprint as ASTar Rollout Accelerates

Q-linea AB ( ($SE:QLINEA) ) has issued an update. Q-linea reported full-year 2025 net sales of SEK 11.1...

1M ago

Q-linea Wins ASTar Contract with Major U.S. Hospital System

Q-linea AB ( ($SE:QLINEA) ) has shared an update. Q-linea AB has signed a contract for the adoption...

2M ago

Q-linea Reshapes US Commercial Leadership to Drive ASTar® Adoption

An announcement from Q-linea AB ( ($SE:QLINEA) ) is now available. Q-linea has announced a reshaping of its...

2M ago

Q-linea Enters South Asian Market With First Distribution Deal in Bangladesh

Q-linea AB ( ($SE:QLINEA) ) has shared an announcement. Q-linea has signed its first distribution agreement in South...

3M ago

Q-linea’s ASTar Chosen to Replace Accelerate Pheno in Italian Laboratories

An announcement from Q-linea AB ( ($SE:QLINEA) ) is now available. Q-linea has been selected to supply its...

3M ago

Q-linea Secures First U.S. Hospital Deployments of ASTar Rapid Testing System

Q-linea AB ( ($SE:QLINEA) ) has shared an update. Q-linea AB has achieved its first clinical implementations of...

3M ago

Q-linea AB Expands Share Capital to Strengthen Market Position

The latest announcement is out from Q-linea AB ( ($SE:QLINEA) ). Q-linea AB has increased its total number...

4M ago

Q-linea Announces Organizational Restructuring and Leadership Changes

An announcement from Q-linea AB ( ($SE:QLINEA) ) is now available. Q-linea AB has announced a reorganization and...

4M ago

Q-linea Submits FDA Application for Expanded ASTar BC G- Panel Claims

Q-linea AB ( ($SE:QLINEA) ) has shared an update. Q-linea AB has submitted a 510(k) application to the...

4M ago

QLINEA FAQ

What was Q-linea AB’s price range in the past 12 months?

Q-linea AB lowest stock price was kr20.79 and its highest was kr74.06 in the past 12 months.

What is Q-linea AB’s market cap?

Q-linea AB’s market cap is kr408.72M.

When is Q-linea AB’s upcoming earnings report date?

Q-linea AB’s upcoming earnings report date is Apr 30, 2026 which is in 44 days.

How were Q-linea AB’s earnings last quarter?

Q-linea AB released its earnings results on Feb 04, 2026. The company reported -kr3.733 earnings per share for the quarter, missing the consensus estimate of N/A by -kr3.733.

Is Q-linea AB overvalued?

According to Wall Street analysts Q-linea AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Q-linea AB pay dividends?

Q-linea AB does not currently pay dividends.

What is Q-linea AB’s EPS estimate?

Q-linea AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Q-linea AB have?

Q-linea AB has 18,949,081 shares outstanding.

What happened to Q-linea AB’s price movement after its last earnings report?

Q-linea AB reported an EPS of -kr3.733 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.68%.

Which hedge fund is a major shareholder of Q-linea AB?

Currently, no hedge funds are holding shares in SE:QLINEA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Q-linea AB

Q-linea AB (publ) engages in the development of instruments and consumables for infection diagnostics in Sweden. It offers inventive systems for in vitro diagnostics systems for infectious diseases. The company's lead product candidate is ASTar, an antibiotic susceptibility testing system used for positive blood cultures. It develops and delivers solutions for healthcare providers. Q-linea AB (publ) was incorporated in 2008 and is headquartered in Uppsala, Sweden.